In Action
The AMR Industry Alliance members have a wide range of expertise and work in many different environments. As a result the way they contribution to tackling AMR varies. The case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps they are taking to invest in new research to develop new antibiotics and vaccines, and prevent infection and improve appropriate use of antibiotics! We hope that others can draw on the Alliance members’ successes and failures, and be inspired to also take actions to address AMR.
Click here for our Call to Action
Click here for our roadmap on equitable and responsible access
Click here to review our work in 2024
Click here for our report on principles of pooled procurement
Click here for our manufacturing standard
Click here to review our work in 2023
Click here for our report on why R&D professionals are leaving the lab
We measure and drive the life-sciences industry progress to curb antimicrobial resistance
in four different areas:
research & science
Invest in R&D to meet public health needs with new innovative diagnostics and treatments
appropriate use
Work to reduce the development of antimicrobial resistance
access
Improve access to high-quality antibiotics and ensuring that new ones are available to all
manufacturing
Reduce the environmental impact of manufacturing
AstraZeneca – Integrating human and environmental health in antibiotic risk assessment
Antibiotics are vital in the treatment of bacterial infectious diseases but when released into the environment they may impact non-target organisms that perform vital ecosystem services and enhance an...
BACT’ATTACK®
By 2050, if considerable gains are not made to combat AMR, it could become the main cause of death among all diseases worldwide. In addition to promoting and fostering R&D for AMR-related health p...
CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant
Drug-resistant infections are complex and developing new antibiotics challenging, timely and costly. But restoring the R&D pipeline is vital to address the seriously increasing threat of superbugs...
Mylan – Implementing ‘Zero Liquid Discharge’ at Manufacturing Facilities in India
One main cause of the rise of AMR is the over-prescribing and inappropriate use of antibiotics in or by humans, as well as improper disposal. Another main cause is the use of antibiotics in intensive...
Novartis – KAF156 Molecule
KAF156 was discovered and is being developed to address the lack of new molecules active against malaria parasites. Next-generation antimalarials are urgently needed to secure the gains made over the...
Qiagen – Detection and Surveillance of Antibiotic Resistance Genes From Food and Fertilizer Sources Using qPCR Technology
One potential way to acquire antibiotic resistance genes is through the food supply chain. Both livestock and feed may acquire antibiotic resistant bacteria via different mechanisms. Foodstuffs can be...
Abbott (formerly Alere) – Test Target Treat™
In order to preserve the antibiotics that are currently available we must promote the appropriate use of antibiotics....
Aequor – ABD (Aequor Biofilm Dispersant) Effectively Combats AMR without Toxicity or Triggering Resistance
Aequor's ABD (Aequor Biofilm Dispersant) represents a leap forward in the race between modern medicine and antimicrobial/drug-resistant (AMR) bacteria and fungi. The polymer-like structure of proteins...
AEQUOR’S NOVEL MOLECULES COUNTER BIOFILM ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
Bacteria and fungi can form biofilms that stick to surfaces inside the human body. This process enables microbial cells to become tolerant and resistant to antibiotics, thus making infections more dif...
AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
With the rapid emergence and spread of MDR bacterial infections, antimicrobial resistance (AMR) has become a major global public health threat. Patients in intensive care units (ICUs) are particularly...
ANTABIO – PEi Program
Antimicrobial resistance affects a high percentage of patients suffering from cystic fibrosis. This happens due to a combination of a variety of factors, which includes physiological changes. Thus, in...
BD – “Resistance Fighter” Awareness and Mobilization Campaign
This campaign addresses the need to raise global awareness about antimicrobial resistance (AMR) and the important roles that everyone plays in the fight against its spread. This campaign targets all w...
BD – AMR Education and Training Collaboration with the London School of Hygiene and Tropical Medicine (LSHTM)
Need to build training programs and capacity building for continuous education to help raise awareness of AMR and improve diagnostic utilization....
BD – Phoenix™ M50 System
Targeted antimicrobial therapy. Wrong diagnosis can lead to wrong therapies, which in turn delay treatment and can cause AMR...
BEAM Alliance – Guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field.
Due to their versatile properties, bacteria are evolving resistance faster than policymakers are implementing action. It is of enormous importance to ultimately revive R&D in AMR by developing com...
bioMérieux – Collaborative project with Antwerp University (Pr Herman Goossens)
The importance of surveillance of antimicrobial use and resistance profiles has been clearly recognized in several reports, such as Lord Jim O’Neill’s report with a specific issue dedicated on sur...
BIOMÉRIEUX LEADS EUROPEAN EFFORT TO QUANTIFY DIAGNOSTICS’ VALUE TO COMBAT AMR
...
CENTRIENT AND CIPLA COMBAT IRRATIONAL ANTIBIOTIC USE IN CHINA AND INDIA
Inappropriate and overuse of antibiotics in the world’s two most populous countries pose a danger to their populations. In China, where consumption of antimicrobials is trending downward, irratio...
DSM – Sustainably-produced Antibiotics
Common practice in today’s pharmaceutical manufacturing industry requires large volumes of chemical solvents, produces millions of tonnes of CO2 emissions, and could contribute to the growing threat...
Cepheid – Global Laboratory Initiative
WHO’s global strategy for tuberculosis (TB) prevention, care and control for 2015–2035 (known as the End TB Strategy) calls for the early diagnosis of TB and universal drug-susceptibility testing...
Da Volterra – DAV132
The usage of large-spectrum antibiotics prescribed to treat infections, can generate consequences on patients health linked to the deleterious effects of those antibiotics on the microbiota. It is wel...
Prevention of Post-Surgical Staphylococcal Infections.
Infection prevention initiatives based on widespread antibacterial drug use such as that advocated by recent 2016 WHO prevention of Surgical Site Infection guidelines are compromised by rapid...
GSK – Appropriate Use Initiatives
Antibiotics should only be used in patients who need them. Ensuring antibiotics are used appropriately is a key component of antimicrobial stewardship and GSK believes that industry should support con...
GSK – Improving Access to Antibiotics and Vaccines
GSK recognizes that access to medicines and healthcare should be available to everyone who needs them, no matter where they live or how much they can afford. In many countries, we still need to improv...
GSK – Public-Private Partnerships to Share Knowledge and Expertise in R&D
Due to the complexities of researching new AMR-relevant products, it is important that the industry collaborates with other stakeholders to share knowledge and expertise. This can improve the efficien...
GSK – Responsible Antibiotic Manufacturing
GSK recognises that factory discharges of antibiotics and antimicrobial active materials could contribute to an increase in resistant genes in the environment. GSK is committed to ensuring that discha...
GSK – Sales Incentives Programme and Healthcare Provider Engagement Model
Antibiotics need to be conserved and used appropriately to minimise the development of resistance. Sales and marketing activity focused purely on driving volume of sales risks being counter to what is...
GSK – Survey of Antibiotic Resistance (SOAR)
Understanding local antibiotic drug resistance patterns helps encourage appropriate antibiotic usage; supports development of local antibiotic prescribing guidelines and vaccination strategies; and, m...
GSK DRIVES MANUFACTURING ENVIRONMENTAL STANDARDS
...
iNtRON- N-Rephasin® SAL200 (Tonabacase)
A novel approach and break-through in addressing the problem of antibiotic-resistant bacterial infections. The key features of SAL200 include rapid bacteriocidal activity, antibacterial activity again...
Johnson & Johnson – Access to diagnostics and therapeutic solutions for TB and MDR-TB (with FIND Diagnostics)
While MDR-TB is threatening the global effort to eliminate TB, the high rates of missed or delayed diagnosis are preventing prompt, effective treatment and allowing MDR-TB’s continued spread. The ne...
SIRTURO® (bedaquiline) Development and Launch
Globally, more people die of tuberculosis than any other infectious disease. Drug resistant tuberculosis (MDR-TB) accounts for roughly one-third of all AMR fatalities. Each year, roughly 500,000 peopl...
Leveraging global surveillance data to develop rapid diagnostics: MSD & OpGen’s Collaboration
Rapid diagnostics for pathogen identification and antibiotic susceptibility testing are central to developing global solutions for antimicrobial resistance. Diagnostics can help distinguish between in...
Merck & Co., Inc – Partnering with Local Hospitals Worldwide to Implement Antimicrobial Stewardship (AMS) Programs
Any use of antimicrobials contributes to the development of resistance, but widespread unnecessary and excessive use makes it worse. AMS refers to a collection of interventions geared toward optimizin...
Merck & Co., Inc. – Study for Monitoring Antimicrobial Resistance Trends (SMART)
Surveillance studies can yield important information for identification of trends in pathogen incidence and AMR, and provide early indicators of the emergence of resistant strains. Such studies are fu...
MSD AND THE WELLCOME TRUST INVEST IN TRANSFORMATIVE AFFORDABLE VACCINES
...
Otsuka – FighTBack Initiative
Considering the dramatic rise in bacterial resistance worldwide, rational use of the MDR-TB compound delamanid is critical to ensuring that the greatest number of patients have access to this medicine...
Otsuka – MDR-Tuberculosis R&D
TB bacteria are so resilient that patients must take a regimen of several different medicines for anywhere from six months to a year. In the case of drug-resistant strains such as multidrug-resistant...
Peptilogics – Innovative Peptide-Based Platform to Develop a New Class of Potent Antibiotics
Increasing numbers of U.S. cases of bacterial infections, particularly Gram negative infections in the hospital setting, are resistant to last-resort antibiotics. We are even seeing infections by bact...
Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
Prosthetic Joint Infection (PJI) is one of the most challenging complications of joint arthroplasty and a serious, life threatening condition with few effective treatment options. “Total joint re...
Pfizer – Antimicrobial Access Programs
At Pfizer we believe that access to quality healthcare and the opportunity to lead healthy lives is an extremely important social goal. The power and value of collaboration between public and private...
Pfizer – Antimicrobial Innovative Vaccines
Pfizer has made significant and substantial investments in vaccine R&D to develop new vaccines and to support several vaccines already in clinical usage. It has been clearly demonstrated that bact...
Pfizer – Antimicrobial Testing Leadership and Surveillance (ATLAS)
In the fight against the rise of antimicrobial resistance, it is important to stay abreast of trends in antibiotic resistance as they emerge. But while the US and Europe have public healthcare organiz...
Pfizer – Massive Open Online Course on Stewardship
Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of mechanisms, including medical symposia and Pfizer sponsored preceptorships, to ensure app...
Pfizer, ICMR to Establish a Centre in New Delhi to Combat AMR
The project will help address the growing threat of antimicrobial resistance (AMR) in India, as it is important to invest all the necessary resources in combating the adverse impact of AMR, due to the...
SANDOZ DRIVES REMEDIATION PROGRAM TO HELP MAINTAIN GLOBAL SUPPLIES OF CRITICAL ANTIBIOTIC
...
Shionogi – Antimicrobial Stewardship Program
At Shionogi, antimicrobial stewardship means selecting the best medicine and administration method and ensuring treatment starts and ends at the optimal time, in order to make treatment safe and relia...